Last Updated: May 3, 2026

Details for New Drug Application (NDA): 020944


✉ Email this page to a colleague

« Back to Dashboard


NDA 020944 describes JUNIOR STRENGTH ADVIL, which is a drug marketed by Haleon Us Holdings and is included in two NDAs. It is available from two suppliers. Additional details are available on the JUNIOR STRENGTH ADVIL profile page.

The generic ingredient in JUNIOR STRENGTH ADVIL is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and forty-three suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.
Summary for 020944
Tradename:JUNIOR STRENGTH ADVIL
Applicant:Haleon Us Holdings
Ingredient:ibuprofen
Patents:0
Pharmacology for NDA: 020944
Mechanism of ActionCyclooxygenase Inhibitors
Medical Subject Heading (MeSH) Categories for 020944
Analgesics, Non-Narcotic
Anti-Inflammatory Agents, Non-Steroidal
Cyclooxygenase Inhibitors
Suppliers and Packaging for NDA: 020944
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CHILDREN'S ADVIL ibuprofen TABLET, CHEWABLE;ORAL 020944 NDA Haleon US Holdings LLC 0573-0179 0573-0179-20 1 BOTTLE in 1 CARTON (0573-0179-20) / 24 TABLET, CHEWABLE in 1 BOTTLE
CHILDREN'S ADVIL ibuprofen TABLET, CHEWABLE;ORAL 020944 NDA Proficient Rx LP 71205-425 71205-425-24 1 BOTTLE in 1 CARTON (71205-425-24) / 24 TABLET, CHEWABLE in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:OTCDosage:TABLET, CHEWABLE;ORALStrength50MG
Approval Date:Dec 18, 1998TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:OTCDosage:TABLET, CHEWABLE;ORALStrength100MG
Approval Date:Dec 18, 1998TE:RLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links